Akoya Biosciences Inc AKYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AKYA is a good fit for your portfolio.
News
-
Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
-
Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
-
Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
-
Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board
-
Akoya Biosciences Shares Jump on 2024 Outlook, Thermo Fisher Deal
-
Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook
-
Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow
-
Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform
Trading Information
- Previous Close Price
- $4.73
- Day Range
- $4.59–4.79
- 52-Week Range
- $3.04–8.80
- Bid/Ask
- $4.69 / $4.71
- Market Cap
- $230.47 Mil
- Volume/Avg
- 136,367 / 217,830
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler® (formerly CODEX) and PhenoImager® (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Value
- Total Number of Employees
- 330
- Website
- https://www.akoyabio.com
Comparables
Valuation
Metric
|
AKYA
|
RXRX
|
AAGH
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.28 | 5.03 | — |
Price/Sales | 2.16 | 47.23 | 294.00 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
AKYA
|
RXRX
|
AAGH
|
---|---|---|---|
Quick Ratio | 2.83 | 4.24 | 0.03 |
Current Ratio | 3.45 | 4.70 | 0.08 |
Interest Coverage | −6.62 | −3,620.07 | −1.37 |
Quick Ratio
AKYA
RXRX
AAGH
Profitability
Metric
|
AKYA
|
RXRX
|
AAGH
|
---|---|---|---|
Return on Assets (Normalized) | −30.67% | −41.77% | −281.13% |
Return on Equity (Normalized) | −93.26% | −59.93% | — |
Return on Invested Capital (Normalized) | −36.71% | −57.52% | — |
Return on Assets
AKYA
RXRX
AAGH
Medical Instruments & Supplies Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ISRG
| Intuitive Surgical Inc | Szyndwnwg | Dbly | $141.5 Bil | |
BDX
| Becton Dickinson & Co | Kdzpdbmq | Xfsfwz | $71.5 Bil | |
ALC
| Alcon Inc | Fxjwwyhl | Qzvsg | $40.7 Bil | |
CLPBY
| Coloplast A/S ADR | Xdscjhpf | Nqxt | $30.4 Bil | |
RMD
| ResMed Inc | Pkdqcvzwgg | Cmfkcf | $29.1 Bil | |
WST
| West Pharmaceutical Services Inc | Fjwncnwjpt | Mjlh | $29.0 Bil | |
BAX
| Baxter International Inc | Fgtcxggg | Bhmgm | $21.8 Bil | |
COO
| The Cooper Companies Inc | Lkchnqg | Rjbgby | $20.2 Bil | |
HOLX
| Hologic Inc | Ltcbzcr | Ldfjhrl | $18.3 Bil | |
TFX
| Teleflex Inc | Mdjbg | Tmvhk | $10.6 Bil |